- Telehealth Visits
- Insurance plan information
Andrew G. Taylor, MD, PhD
Interventional RadiologyDirector of Quality, Interventional Radiology- Telehealth Visits
- Insurance plan information
Andrew G. Taylor, MD, PhD
Interventional RadiologyDirector of Quality, Interventional Radiology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Andrew G. Taylor specializes in interventional oncology, using imaging technologies for targeted treatment of cancers, especially tumors of the liver, prostate and kidneys. His expertise also encompasses venous interventions, such as placing and managing inferior vena cava filters (implantable devices that can prevent blood clots from traveling to the lungs), and new methods of molecular imaging, such as hyperpolarized carbon-13 magnetic resonance imaging.
Taylor earned his medical degree and a doctorate in biomedical engineering from the University of Pennsylvania. At UCSF, he completed a residency in diagnostic radiology, followed by a fellowship in vascular and interventional radiology.
Education & training
Board certification
- Interventional and Diagnostic Radiology, American Board of Radiology
Fellowship
- Interventional Radiology, University of CA at San Francisco Radiology GME
Residency
- Diagnostic Radiology, University of CA at San Francisco Radiology GME
Internship
- Internal Medicine, Pennsylvania Hospital
Degree
- MD, University of Pennsylvania School of Medicine
My expertise
Specialties
Clinical Trials query: q=health_gateway_id_ss%3A%28%221397%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%221397%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.